TriSalus Life Sciences Inc reports results for the quarter ended June 30 - Earnings Summary

• TriSalus Life Sciences Inc TLSI.OQ reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of seven analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -27 cents to -19 cents per share.

• Revenue rose 52.3% to $11.21 million from a year ago; analysts expected $10.69 million.

• TriSalus Life Sciences Inc's reported EPS for the quarter was a loss of 27 cents​.

• The company reported a quarterly loss of $9 million.

• TriSalus Life Sciences Inc shares had fallen by 34.5% this quarter and lost 28.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 26.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $11.00, about 67.5% above its last closing price of $3.57

This summary was machine generated from LSEG data August 12 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)